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To compare tissue-based pharmacokinetics and efficacy of oral tenofovir disoproxyl fumarate (TDF) versus subcutaneous teno-
fovir (TFV), macaques were treated for 2 weeks starting 1 week after simian immunodeficiency virus inoculation. Despite lower
plasma TFV levels in the oral TDF arm, similar TFV diphosphate levels and antiviral activities were measured in lymphoid cells
of most tissues. In intestinal tissues, however, oral TDF resulted in higher active drug levels, associated with lower virus levels
and better immune preservation.
While our ability to manage HIV infection with chronic anti-retroviral therapy represents a triumph of modern medi-
cine, researchers are now on a quest to find strategies to com-
pletely cure or permanently control HIV infection in the absence
of chronic antiretroviral drug treatment (7). Success is likely to
depend on a better understanding of the dynamics of viral reser-
voirs, including residual virus replication and latency, and its in-
terplay with pharmacokinetics and pharmacodynamics. Data sug-
gest that levels of HIV and drugs in blood are not always
representative of their levels in the lymphoid tissues, where most
virus replication occurs (6).
One of the drugs most widely used to treat HIV infection is
tenofovir (TFV). Following two phosphorylation steps, the phar-
macologically active intracellular metabolite tenofovir diphos-
phate (TFV-DP) inhibits viral reverse transcription. Because TFV
is hydrophilic, it has very poor oral bioavailability. Therefore, TFV
is administered orally as the fumarate salt of its lipophilic and
more cell-permeant disoproxyl prodrug (tenofovir disoproxyl fu-
marate [TDF]). TDF has 500-fold greater anti-HIV activity in
vitro than TFV (23). As TDF is not observed in plasma at the
earliest time points tested following administration to patients
and has a reported half-life of less than 1 min (3, 17, 18), one might
assume that it does not affect the loading of lymphoid cells or
tissues with the active metabolite.
However, data from a small human study suggest that based on
plasma drug levels, the oral administration of TDF had stronger
antiviral effects than parenteral administration of TFV (3, 8). In
addition, a pharmacokinetic study in macaques demonstrated
previously that an oral TDF regimen, selected to give plasma ex-
posures equivalent to those achieved with a subcutaneous TFV
regimen, resulted in approximately 8-fold-higher levels of
TFV-DP in peripheral blood mononuclear cells (PBMC). Because
that study looked only at drug levels in blood, the present study
was designed to compare TFV and TDF in simian immunodefi-
ciency virus (SIV)-infected animals, including the measurement
of drug and virus levels in lymphoid tissues. Special attention was
given to the gut-associated lymphoid tissue (GALT), which, har-
boring the majority of the body’s lymphoid tissue, is a major site of
virus replication and pathogenesis (4). We hypothesized that, be-
cause of the administration route, oral TDF administration may
result in preferential uploading of drug in GALT, relative to other
lymphoid tissues and relative to parenteral TFV injection.
All 12 animals were healthy juvenile (41 to 43 months of age)
male rhesus macaques (Macaca mulatta), from the HIV-2-, SIV-,
type D retrovirus-, and simian T-cell lymphotropic virus type
1-free colony at the California National Primate Research Center
(CNPRC). Animals were housed in accordance with American
Association for Accreditation of Laboratory Animal Care stan-
dards. We strictly adhered to the Guide for the Care and Use of
Laboratory Animals, prepared by the Committee on Care and Use
of Laboratory Animals of the Institute of Laboratory Resources,
National Resource Council (21). For blood collections and oral
drug administrations, animals were immobilized with ketamine
HCl (Parke-Davis, Morris Plains, NJ) at a dose of 10 mg/kg of
body weight, injected intramuscularly.
At time zero, all 12 animals were inoculated intravenously with
1 ml containing 103 50% tissue culture infectious doses (equiva-
lent to 103 50% animal infectious doses) of virulent uncloned
SIVmac251. The titer of this stock (designated 6/04), which was
propagated in rhesus macaque PBMC, had been determined in
vitro and in vivo (20). One week after SIV inoculation, animals
were randomized to three treatment groups of four animals each.
TFV and TDF solutions were prepared at 60 mg/ml and 8 mg/ml,
respectively, as described previously (9), while placebo treatments
consisted of sterile physiologic saline (0.9% NaCl). One group
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received TFV subcutaneously at 6 mg/kg, while the second group
received TDF orally at 22 mg/kg (via intubation to ensure full drug
uptake). Both TFV and TDF treatment groups received also pla-
cebo treatment via the other route (oral and subcutaneous, re-
spectively). The third group (“placebo”) received placebo by both
the oral and subcutaneous routes. All animals were dosed once
daily, and samples were taken every few days, with 24-hour phar-
macokinetic studies performed on day 7 (after the first dose) and
day 20 (after the last dose). On day 21, all animals were euthanized
for analysis of drug levels, virus levels, and immune markers in
blood and tissues.
Previously described methods, including collagenase digestion
techniques used for gut tissues, were used to separate plasma and
isolate mononuclear cells from blood and tissue samples (1, 9, 24).
The use of phosphate-buffered saline was avoided during sample
preparation due to its negative effects on the analysis of TFV-DP
(9). Mononuclear cells were treated with NH4Cl to remove con-
taminating red blood cells as described previously and then cryo-
preserved immediately at 70°C until further analysis. Plasma
TFV and intracellular TFV-DP levels were measured as described
previously (9).
The drug regimens used in this study were calculated using
repeated-dose pharmacokinetic modeling, using the data from
our previous single-dose pharmacokinetic study in uninfected
age-matched animals (9). We selected oral and subcutaneous
doses aimed at achieving similar steady-state plasma exposures
after repeated dosing, but with the hypothesis that the oral TDF
regimen would provide higher intracellular levels of TFV-DP and
thus higher antiviral activity than the subcutaneous regimen of 6
mg/kg (which is likely suboptimal in comparison to the subcuta-
neous 30 mg/kg induction regimen routinely used to suppress SIV
replication in macaques [27]). However, despite this initial aim to
achieve similar drug levels in plasma with the subcutaneous TFV
and oral TDF regimens, marked differences in plasma pharmaco-
kinetics were observed in the SIV-infected animals (Fig. 1A). The
maximum concentration (Cmax) was higher and terminal elimi-
nation half-life shorter following subcutaneous TFV than after
oral TDF. Slight accumulation was observed in plasma TFV expo-
sures (area under the concentration-time curve from 0 to 24 h
[AUC0-24]) between days 7 and 20 following administration of
subcutaneous TFV (15% increase in mean AUC0-24) or oral TDF
(32% increase in mean AUC0-24). The plasma TFV AUC0-24 values
on day 20 following subcutaneous TFV daily versus oral TDF ad-
ministration were 38.1  2.8 versus 10.9  2.4 M · h, respectively
(mean  standard deviation [SD], n  4; P  0.001, two-tailed t
test) (Fig. 1B). While these plasma TFV levels achieved in the
subcutaneous TFV regimen were consistent with previous obser-
vations, the values for oral TDF were lower than predicted based
on values obtained with uninfected animals (9). In hindsight, the
most likely explanation is poor absorption of TDF associated with
the gastrointestinal dysfunction that has been observed during
acute infection with virulent SIV, even without outward signs of
diarrhea or detectable opportunistic intestinal pathogens (15).
Despite this 3.5-fold-lower TFV plasma exposure (AUC0-24)
FIG 1 Extracellular and intracellular TFV pharmacokinetics following subcutaneous TFV versus oral TDF administration. (A and B) Levels of TFV in plasma
and values for area under the plasma concentration-versus-time curve (AUC0 –24), respectively, for day 7 and day 20 of drug administration. (C) Accumulation
of TFV-DP in PBMC collected on the respective study days, exactly 24 h after the drug dosing on the previous day. (D and E) Intracellular levels of the active
metabolite TFV-DP in mononuclear cells from blood or tissues at the time of euthanasia on day 21. All values are means  SD for samples collected from four
animals, except for jejunum and rectum samples from the subcutaneous-tenofovir group, where samples were collected from two animals.
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following oral TDF relative to subcutaneous TFV, the intracellular
levels of TFV-DP in PBMC turned out to be very similar in the two
groups (Fig. 1C and D). Consistent with the data in the prior
pharmacokinetic study, these results suggest that tenofovir diso-
proxil plays a direct role in drug delivery to lymphoid cells and
tissues (9). Evidence of accumulation of TFV-DP was observed in
PBMC samples from both treatment groups, particularly the first
week of treatment. On day 21 (24 h after the last dosing), PBMC
TFV-DP levels were an average of 105 fmol/million cells (i.e., 525
nM, assuming a volume of 0.2 pl/cell for PBMC) (Fig. 1D), which
is more than 4-fold higher than the TFV-DP levels observed 24 h
after the initial dosing on day 7 (P  0.001, two-tailed t test) (Fig.
1C). These steady-state levels of TFV-DP in PBMC on day 21
resemble those observed in HIV-infected humans taking the oral
TDF tablet daily (average, 100 fmol per million PBMC) (2, 13,
14, 22). At the time of euthanasia on day 21, TFV-DP levels in four
different lymph nodes and spleen were also similar for both treat-
ment regimens, averaging 23.8 fmol/million cells (Fig. 1D). An
exception to this was the gastrointestinal tract, where levels of
TFV-DP were 250-fold higher in jejunum and 16-fold higher in
rectal tissue following oral TDF than after subcutaneous TFV ad-
ministration (Fig. 1E). Higher TFV-DP levels in gut tissue than in
other lymphoid tissues in uninfected macaques receiving oral
TDF have also been reported (11).
To monitor the effect of drug administration on virus replica-
tion, a real-time reverse transcription-PCR (RT-PCR) assay for
SIV gag was used to quantitate SIV RNA levels in plasma and in
total RNA extracted from tissues collected in RNAlater (Ambion,
Austin, TX) and processed according to methods described pre-
viously (1, 5). As predicted, all animals had high peak viremia
(107 SIV RNA copies/ml plasma) by day 7 or 10 after SIVmac251
inoculation (Fig. 2A to D). The three groups had nearly identical
SIV levels at day 7, when treatment was started. A decline in
viremia was observed from day 10 onward, but the virological
response in the two drug-treated groups was smaller than ex-
pected and remarkably similar in both treatment groups, which is
consistent with the pharmacokinetic data (i.e., suboptimal drug
levels early on and similar TFV-DP levels in the majority of tissues
for the two drug-treated groups). At the time of euthanasia (day
21), the mean plasma SIV levels in the TDF- and TFV-treated
groups were nearly identical and approximately 2-fold (0.35 log)
lower than those in the placebo group, but due to considerable
variability, this difference was statistically not significant (Fig. 2E
and F). SIV RNA levels in tissues collected on day 21 were also
highly variable, but the most interesting difference was observed
in the jejunum, where mean SIV RNA levels in the subcutaneous
TFV and oral TDF treatment groups were 3-fold and 7-fold lower
than those in the placebo group, respectively (Fig. 2G).
Because previous studies have demonstrated that tenofovir
monotherapy selects for the emergence of K65R RT viral mutants
with reduced in vitro susceptibility, sensitive real-time PCR meth-
odology (with a detection limit of 0.4%) was used to quantitate
K65R mutants (16, 26). At the time of euthanasia, K65R viral
mutants were detected at a frequency of 0.8% in plasma and jeju-
num of TFV-treated animal 36243. The other tissues of this ani-
mal and all samples from the remaining animals had only wild-
type sequence. Of all drug-treated animals, animal 36243 was the
one with the highest peak plasma RNA levels (8  107 copies/ml
on day 10). This observation of the earliest detection of K65R
mutants in jejunal tissue is consistent with the role of gut-associ-
ated lymphoid tissue as a major target of virus replication and
source of plasma viremia (4, 19). These findings also suggest the
importance of obtaining suppressive drug levels in the tissues
(6, 10).
At every blood collection, lymphocyte subpopulations were
phenotyped for CD3, CD4, CD8, and CD20. In addition, at the
time of euthanasia, additional markers were used to detect mem-
ory and effector cells (using CD28 and CD95) in cells from blood
and tissues. Because of high variability, there were no clear biolog-
ically relevant differences in any of the lymphocyte markers, with
the exception of a trend toward better preservation of central
memory CD4	 cells in drug-treated animals, particularly in the
gut-associated lymphoid tissues (oral TDF  subcutaneous TFV
 placebo) (Fig. 2H to J). Because central memory cells are rapidly
depleted during acute SIV infection (4, 19), this observation of
preservation of memory CD4	 T cells is consistent with the higher
TFV-DP levels and lower viral RNA levels in the gut with the oral
TDF regimen than with the subcutaneous TFV regimen.
At the time of euthanasia, SIV-specific cell-mediated immune
responses were evaluated in PBMC and lymphoid tissues (tonsil,
spleen, jejunum, rectum, and four different lymph nodes). Intra-
cellular cytokine production (interleukin 2 [IL-2], gamma inter-
feron [IFN-
], and tumor necrosis factor alpha [TNF-]) and cell
surface expression of the degranulation marker CD107 were as-
sessed via multiparameter flow cytometry from fresh PBMC and
lymphoid cells after stimulation with SIV antigens (aldrithiol-2
[AT-2]-inactivated whole SIVmac239; overlapping 15-mer pep-
tides spanning the SIV gag p27 protein) according to methods
reported previously (25). While all animals had some CD4	 and
CD8	 cell-mediated immune responses, responses were nearly all
monofunctional (i.e., one cytokine, mostly IFN-
 or TNF-), and
the magnitude was generally low and highly variable among tis-
sues and among animals. There were no obvious biologically rel-
evant differences between the treatment groups. These observa-
tions are consistent with an early, immature immune response
during acute viremia with the highly virulent SIVmac251 that
causes rapid immune dysfunction. As previous studies have dem-
onstrated that antiviral immune responses play an important role
in reducing viremia at the start of TVF therapy (27), these poor
antiviral immune responses during acute infection likely contrib-
uted to the suboptimal virologic response in the two drug-treated
groups.
In summary, despite the suboptimal virologic response due to
lower-than-predicted absorption of the oral TDF regimen and
immature antiviral immune responses, the present study is infor-
mative in several regards. First, it confirms in SIV-infected ani-
mals that administration of oral TDF more efficiently loads lym-
phoid cells with reduced plasma exposure. The advantage of oral
prodrug administration in loading of relevant tissues was magni-
fied in the gut, presumably due to direct intestinal exposure to a
highly cell-permeant prodrug (11). These higher active-drug lev-
els are relevant to the use of antiretroviral drugs like TDF in pre-
exposure prophylaxis regimens against rectal virus transmission
(11, 12). Second, this study demonstrates that drug levels mea-
sured in plasma or PBMC may not be reflective of intracellular
drug levels in lymphoid tissues, and therefore, such correlations
probably need to be established separately for every drug (2, 6).
Tissue-dependent differences in active drug levels and availability
of target cells for virus replication likely play an important role in
the selection of drug-resistant viral mutants. Altogether, these ob-
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servations provide further scientific impetus for the design and
clinical development of other prodrugs of tenofovir (e.g., GS-7340
[18]) and/or other antiretroviral drugs that can further enhance
selective targeting of the sites of viral replication and viral reser-
voirs, with the goal of persistently controlling replication, protect-
ing from transmission in the context of pre-exposure prophylaxis,
or ultimately curing infection with finite treatment programs.
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